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Abstract
Endogenous endophthalmitis is an ophthalmic emergency that can have severe sight-threatening complications. It
is often a diagnostic challenge because it can manifest at any age and is associated with a number of underlying
predisposing factors. Microorganisms associated with this condition vary along a broad spectrum. Depending upon
the severity of the disease, both medical and surgical interventions may be employed. Due to rarity of the disease,
there are no guidelines in literature for optimal management of these patients. In this review, treatment guidelines
based on clinical data and microorganism profile have been proposed.
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Introduction
Intraocular infection affecting the inner coats of the eye
associated with significant, progressive vitreous inflam-
mation is termed as endophthalmitis [1–4]. Endophthal-
mitis is an ophthalmic emergency that can result in
devastating ocular and systemic complications. The most
common route of entry of infective organisms is through
an external wound of entry, such as trauma, surgery, or
infected cornea. These cases of endophthalmitis are
termed as exogenous endophthalmitis. Endogenous en-
dophthalmitis (EE), on the other hand, results from the
hematogenous spread of microorganisms from distant
foci [5–7].
EE accounts for approximately 2–8 % of all cases of
endophthalmitis [2, 8–11]. Due to paucity of the disease,
literature on EE mostly comprises of case series or single
case reports. Unlike exogenous endophthalmitis, demo-
graphics, treatment options, and outcome measures in
patients with EE have not been studied in large-scale
studies.
The first case of bacterial EE has been published in
1856 [12]. Subsequently, a major review including ap-
proximately 335 cases of bacterial EE was published in
2003 [11], and the authors have recently updated their
initial data by accommodating further reports [13].
However, there have been no major reviews encompass-
ing all the infective etiologies, including both bacterial
and fungal, in literature. With changing patterns of micro-
bial disease epidemiology, re-emergence of certain infec-
tious diseases, antibiotic susceptibility, and development
of superbugs, a systematic reappraisal of EE is necessary.
Causative organisms
The etiology of EE is multifactorial, and the list of causa-
tive organisms is extensive, with significant geographic
variation. Both bacterial and fungal agents are noted in
the literature as potential agents of EE in the developed
world. However, fungal organisms account for the major-
ity of the cases [9, 10]. The organisms responsible for bac-
terial EE differ depending on the geographic location. In
the developed world, gram-positive organisms (Strepto-
cocci and Staphylococci) dominate the infection, whereas
gram-negative organisms are more common in the Asian
population [9, 14]. Asian studies have reported fungi as
the causative organisms in approximately 11.1 to 17.54 %
of total cases of EE, with the rest being attributed to bac-
terial causes [14, 15].
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Risk factors
EE is frequently associated with many underlying systemic
risk factors [3, 5, 10, 16–23]. The most common risk
factors include recent hospitalization, diabetes mellitus,
urinary tract infection, immunosuppression (especially
associated with underlying malignancy, neutropenia, and
HIV (human immunodeficiency virus)), intravenous drug
abuse (IVDA), and indwelling catheters [10].
Liver abscesses have been noted to be associated with
EE, especially those caused by gram-negative rods such
as Klebsiella pneumonia [24]. In most of these cases
with Klebsiella, diabetes is the major underlying sys-
temic risk factor [25, 26]. This finding is most promin-
ently noted in the Asian population where bacterial
endophthalmitis is more common [15]. Infective endo-
carditis (IE) is another important risk factor commonly
associated with EE in the western countries [27, 28].
Various causes of transient bacteremia such as routine
colonoscopy can also lead to EE [29].
According to a study assessing differences between the
risk factors for mold and yeast infections, patients with
mold infections were more likely to be associated with
the use of chemotherapy as well as organ transplantation
especially cardiac and liver transplants [16]. Similar re-
sults have been reported with molds as a common cause
of EE in patients on immunosuppressive therapy for
hematopoietic stem cell transplantation (HSCT) or for
any hematological malignancy [30]. Patients with lung
involvement by Aspergillus are at a specially increased
risk for developing EE [4, 30, 31].
Neonatal endogenous endophthalmitis deserves a special
mention. Unlike endophthalmitis in adults, neonatal cases
are overwhelmingly as a result of an endogenous source of
infection. Neonates with candidemia, bacteremia, and ret-
inopathy of prematurity and low birth weight are at signifi-
cant risk for developing EE [32–34]. According to a large
cohort study, the odds of neonates with bacteremia, candi-
demia, and retinopathy of prematurity to develop EE are
21.11, 2.36, and 2.05, respectively (p < 0.0001) [32]. The
causative organisms are often bacteria from Streptococci
species, especially S. agalactiae, gram-negative rods like
Klebsiella or Pseudomonas and fungi including Candida
species. A recent report suggested decreasing incidence of
neonatal EE in the developed world [32].
It is important to note that EE has also been reported
in immunocompetent patients without underlying pre-
disposing conditions. EE may be the first manifestation
of an underlying occult systemic focus of infection, while
the systemic cultures for infective organisms are still
negative [35–39].
Pathophysiology
Endogenous endophthalmitis results from metastatic
spread of the organism from a primary site of infection
in the setting of bacteremia or fungemia [40]. Most
frequently, the organism reaches the eye through the
posterior segment vasculature. The right eye is more
commonly involved probably due to the more direct
route through the right carotid artery [40]. Direct spread
from contagious sites can also occur in cases of central
nervous system infection via the optic nerve [41]. Unlike
postoperative and posttraumatic endophthalmitis where
tissue damage results primarily from toxins produced by
the organism, it is postulated that in endogenous en-
dophthalmitis, damage is most probably due to a septic
embolus that enters the posterior segment vasculature
and acts as a nidus for dissemination of the organism
into the surrounding tissues after crossing the blood-
ocular barrier to cause microbial proliferation and in-
flammatory reactions within these tissues. Infection then
extends from the retina and the choroid into the vitre-
ous cavity and thereafter to the anterior chamber of the
eye [42].
Clinical features
The diagnosis of EE may be difficult because of the vari-
ability in the clinical signs and symptoms. The organisms
causing EE gain access to the internal ocular tissues
through the blood-ocular barrier [43]. Due to progressive
inflammation, the patients may experience decreased
vision, which is the most common reason for visiting a
doctor [5, 18, 37]. The other classic features include eyelid
edema, conjunctival injection, circumcorneal congestion,
pain, photophobia, and the presence of floaters [5]. Anter-
ior chamber inflammation with hypopyon, absent red
reflex, vitreous cells, and haze may also occur [21, 28].
These findings of anterior chamber involvement are more
common in bacterial causes of EE [6]. There may be a
poor view of the fundus due to the presence of exudates
and vitreous haze. Other findings include corneal edema,
presence of iris nodules, and pupillary distortion sec-
ondary to synechiae formation [44, 45]. Bilateral in-
volvement can also occur. Causative organisms such
as Mycobacterium tuberculosis can present with bilateral
endogenous endophthalmitis and scleral inflammation
(Fig. 1).
The hallmark of EE is significant involvement of the
vitreous cavity. Vitreous involvement by Candida can
present as vitritis or fluffy white retinal lesions extending
into the vitreous [43]. Aspergillus can present as yellow/
white lesions which can be focal or diffuse [4, 20, 37]
(Fig. 2). If the media clarity permits, retinal hemorrhage
and cotton wool spots may be visualized on examination
[37]. Severe vitreal involvement in bacterial EE can
present with a sub-retinal and choroidal abscess [46].
Methicillin-resistant Staphylococcus aureus (MRSA) as-
sociated endophthalmitis is associated with high rates of
retinal detachment especially when the time period
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Fig. 1 A case of bilateral tubercular endogenous endophthalmitis with scleritis. a Slit lamp biomicroscopy of the left eye with diffuse and
circumcorneal congestion and scleral involvement. There is corneal edema and opacification superiorly. The pupil has broad-based synechiae,
and the view of the posterior segment was hazy. b The right eye with severe congestion and ciliary injection. There was a yellow glow present
(visible near the inferior pupillary border). c A wide-angled fundus photograph of the left eye with vitreous haze secondary to vitritis along with
focal sheathing of superior vessels. The fluorescein angiography (d) shows presence of superior perivascular hyperfluorescence and leakage of
dye in the superotemporal periphery
Fig. 2 Fundus photograph of a 78-year-old male (a) with a yellow white mass in the temporal paramacular region with some superficial
hemorrhages suggestive of a choroidal abscess. The patient was diagnosed with Nocardia endophthalmitis based on retinal aspirates (d, e).
b Fundus photograph taken at 3 weeks following intravenous trimethoprim-sulfamethoxazole therapy. There was a marked resolution of the
lesion and improvement in media clarity at month 3 (c). d Hematoxylin-eosin staining (×20) of the retinal aspirate. e Gram-positive branching rods
of Nocardia species (×40)
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between onset of symptoms and presentation is delayed
by more than 2 weeks [3]. Other non-specific findings
can include flame-shaped hemorrhages, Roth spots and
cotton wool spots [6, 45].
Clinical findings in EE can be subdivided into three
categories to aid the ophthalmologist to rule in the diag-
nosis. Positive signs are strongly suggestive of endogenous
endophthalmitis, whereas probable signs are non-specific
but could be present in a case of EE. Table 1 provides a list
of clinical signs associated with EE.
Visual acuity, as explained above, can be variably af-
fected at the time of presentation, but is generally used as
an outcome measure along with a dilated funduscopic
examination to follow up the patient after starting treat-
ment. A relative afferent pupillary defect (RAPD) can also
be present and can guide the need for a vitrectomy [26].
A large study was conducted to assess the involvement
of eyes in patients with candidemia. A total of 370
patients were enrolled; among them, 60 (16.2 %) patients
were found to have ocular manifestations on fundoscopic
examination. Among these 60 subjects with ocular
involvement, 6 patients were diagnosed with EE [43]. In
approximately 18 % of the patients, new lesions were seen
after an initial negative funduscopic examination. This led
to a hypothesis that there is a significant time delay
between seeding and development of visible retinal le-
sions; therefore, patients may have a normal retinal exam
initially.
In order to classify the severity of ocular involvement
in EE, numerous attempts have been made to classify
the disease. However, there is no unifying broadly
accepted classification for EE available till date. Ishibashi
et al. and Petit et al. have previously proposed clinical
classifications of fungal EE [47, 48].
Diagnosis
The diagnosis of EE requires a high index of suspicion
with presence of one of the above mentioned systemic
risk factors and/or presence of characteristic ocular find-
ings on detailed ophthalmoscopic examination (Table 1)
[49]. However a clinical diagnosis of EE is always diffi-
cult as it has a high false negative rate for EE [5, 49].
Multiple clinic visits may be required to confirm the
diagnosis. It is also important to note that the presence
of EE is generally not among the major concerns in pa-
tients with life-threatening invasive fungal diseases or
sepsis secondary to a bacterial etiology [50], and hence
the diagnosis of EE may be delayed with other morbid-
ities being managed acutely.
To confirm the presence of a specific etiology, vitreous
aspiration and diagnostic vitrectomy followed by a cul-
ture and histological examination are commonly used
[16, 43, 51]. The need for a diagnostic vitrectomy is
dependent on the clinician’s judgment. Vitrectomy has a
higher diagnostic yield for culture (92 %) compared to a
vitreous aspirate (44 %) as shown by Lingappan et al. [5].
Similar results were obtained in another study with nee-
dle biopsy negative cases growing organisms on culture
following vitrectomy [52]. The study showed that vitre-
ous samples during vitrectomy were taken near the ret-
inal surface, which can potentially explain the lower
yield of needle biopsy as early or localized infection
located near the retinal surface might be missed by a
needle biopsy [16].
Another emerging technique is the use of real-time
polymerase chain reaction (RT-PCR) of aqueous and vit-
reous samples for detection of the etiology of EE. Sugita
et al. reported excellent sensitivity as well as specificity
of RT-PCR for detection of fungi [53]. In the same study,
PCR was able to detect causative fungi in 5 culture nega-
tive specimens. This technique has the advantage of
rapid diagnosis (within 90 min), better detection than
cultures as well as no fear of contamination of culture
samples yielding false positive results [10, 54, 55]. Somya
et al. in their study demonstrated increased sensitivity of
PCR over culture [56]. PCR-Based techniques can be
used to rule out the presence of pathogens with confi-
dence, which is a unique advantage of this methodology.
This diagnostic tool promises to be useful in the man-
agement of patients with endophthalmitis, especially in
samples that are culture negative [57]. However, a po-
tential disadvantage of this diagnostic technique is the
inability to determine antibiotic susceptibility [21].
The most reliable way of diagnosing systemic infec-
tion is blood culture. Blood must be drawn on three
Table 1 Ocular signs suggestive of endogenous endophthalmitis
[13, 42]
Positive Possible Probable
Uveal tissue abscesses Hypopyon≤ 1.5 mm Conjunctival injection/
chemosis
























Varying combination of symptoms may be present
aIn a neonate presenting with white reflex, endogenous endophthalmitis can
be considered in the differential diagnosis
Sadiq et al. Journal of Ophthalmic Inflammation and Infection  (2015) 5:32 Page 4 of 11
consecutive days using sterile precautions. Previous
large series have shown higher rates of positivity fol-
lowing blood culture as compared to vitreous aspirate
possibly due to larger volume sampled. It is also import-
ant to culture other extra ocular sites to identify the pos-
sible nidus of infection and guide systemic therapy
accordingly, for example, urine cultures. Confirmatory
identification of extra ocular sources of infection are re-
ported in 21–100 % of cases in the literature [5, 18, 21].
Identification of these infectious foci is particularly im-
portant in cases where vitreous cultures are negative [15].
Imaging of ocular tissues is an important means to
diagnose intraocular infection. Presence of exudates in
the vitreous cavity can present as echoes in the ultra-
sound B-scan of the eye. Patients with EE can present
with abscesses in the choroid (Fig. 2). These can be de-
tected as dome-shaped lesions arising from the choroid
on B-scan. Complications of EE, including retinal detach-
ment may be difficult to assess clinically. In such situa-
tions, ultrasound B-scan can help in identification of
retinal detachment (Fig. 3). Optical coherence tomography
(OCT) has also been used as an imaging modality in
patients with EE where it helps in localizing the pathology
within the retinal layers as well as sub-retinal space
[58, 59]. It can demonstrate sub-retinal exudates with
elevation of retinal pigment epithelium, intra-retinal le-
sions with or without extrusion into the vitreous, chor-
oidal thickening, and posterior vitreous cells [59, 60].
Treatment
As an ophthalmological emergency, prompt manage-
ment is required for any patient with suspected EE.
Approach to management of such a patient involves as-
sessment of degree of ocular involvement, identification
of the causative organism, and the underlying source of
infection and then treatment of both the endophthalmi-
tis and the underlying systemic infection. Summary of
the steps in the diagnosis and management of EE are
illustrated in Fig. 4.
Bacterial endogenous endophthalmitis
Systemic therapy
Treatment of the underlying source of bacteremia is ne-
cessary with systemic antibiotics. Systemic antibacterial
therapy should be initiated after blood cultures have
been obtained. However, treatment with systemic antibi-
otics tailored to systemic infection alone is not sufficient,
and most patients with severe endogenous bacterial en-
dophthalmitis may require intravitreal antibiotics. In
addition, pars plana vitrectomy (PPV) may also be needed
for the treatment of endogenous bacterial endophthalmitis.
Local therapy
Cultures of vitreous obtained by needle aspiration or
vitrectomy are indicated as soon as infectious endoph-
thalmitis is suspected. Timing of administration of the
intravitreal antibiotics has not been officially established;
however, Yonekawa et al. showed that early administra-
tion, i.e., within 24 h, was associated with a favorable
outcome [28]. Treatment is first initiated with empirical
intravitreal antibiotics that provide a cover for both
gram-positive and gram-negative organisms, when the
etiology is unknown. These include vancomycin 1 mg/
0.1 ml plus either ceftazidime 2.25 mg/0.1 ml or amika-
cin 0.4 mg/0.1 ml [12, 26, 44]. For gram-positive infec-
tions, vancomycin is the primary drug used because of
emergence of many cases of methicillin-resistant organ-
isms [28]. However, recently, there have been reports of
gram-positive cases resistant to vancomycin [61]. Khera
et al. reported seven cases of EE caused by vancomycin-
resistant bacteria [62].
There are multiple therapeutic agents that can be used
for gram-negative infections. The most commonly used
drug to provide gram-negative coverage is ceftazidime
(2.25 mg/0.1 ml) or amikacin (400 μg/0.1 ml) [14, 28,
63]. Fluoroquinolones also have good gram-positive and
gram-negative coverages, especially the fourth gener-
ation fluoroquinolones [61]. However, recently, resist-
ance against fluoroquinolones is on a rapid rise [64–66].
Antibiotics can be tailored further once the organism is
identified and susceptibility pattern is known from vitre-
ous and blood cultures. Table 2 lists the most commonly
used intravitreal antibiotics.
Early diagnosis and treatment is essential for a better
prognosis. However, patients with endogenous bacterial
endophthalmitis may have a delayed diagnosis which
may lead to poor prognoses [3, 11, 67].
Two important groups that need special attention while
administering antibiotics are pregnant and breastfeeding
Fig. 3 Ultrasound B-scan of a patient diagnosed with endogenous
bacterial endophthalmitis following septic arthritis. There is presence
of dense, hyper-reflective echoes in the vitreous cavity suggestive of
exudates (yellow arrow). The membrane-like echo in the scan marked
by yellow triangles suggests presence of a total retinal detachment
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women. Penicillins, cephalosporins, and erythromycin are
among the mainline agents in these groups due to good
safety profiles [29]. Fluoroquinolones have been associated
with abnormalities of developing cartilage in animal stud-
ies [68]. Even though there have been no reports of such
cases during human pregnancies, it is recommended to
use fluoroquinolones only when other safer alternatives




For severe vitritis, the best approach appears to be
vitrectomy accompanied by intravitreal injection of
amphotericin or voriconazole and systemic antifungal
therapy [70, 71]. The dose of amphotericin B (AMB)
deoxycholate for intravitreal injection is 5 to 10 mcg in
0.1 ml sterile water or dextrose. This dose appears to be
safe and can be repeated after intervals of 48 h or more
Fig. 4 A proposed management of patients with endogenous endophthalmitis. Signs such as poor visual acuity (≤ perception of light), large
hypopyon, and choroidal abscess make the diagnosis of endophthalmitis very likely. In a neonate with white reflex, endophthalmitis (along with
other considerations such as malignancy) must be kept as a possibility in the differential diagnosis. Sight-threatening lesions involving the fovea, optic
nerve head, cornea, limbus, or sclera may require prompt surgical management. APD afferent pupillary defect, VA visual acuity, LP light perception
Table 2 Commonly used intravitreal antibacterial drugs used for
pharmacotherapy of bacterial endogenous endophthalmitis
Drug Intravitreal dose Reference
A. Gram-positive bacteria (including VSSA)
Vancomycin 1 mg/0.1 ml [12, 26, 44]
Cefazolin 2.25 mg/0.1 ml
B. Gram-positive bacteria—VRSA
Daptomycin 200 μg/0.1 ml [27]
Quinupristin/dalfopristin 0.4 mg/0.1 ml [62]
C. Gram-negative bacteria
Ceftazidime 2.25 mg/0.1 ml [12, 26]
Amikacin 0.4 mg/0.1 ml [89]
VSSA vancomycin sensitive staphylococcus aureus, VRSA vancomycin resistant
staphylococcus aureus
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if there is evidence of persistent intraocular infection.
Systemic administration of AMB is associated with dose-
limiting nephrotoxicity, hypotension, arrhythmias, and
infusion-related fever and chills (“shake and bake”) [8].
Voriconazole is a newer agent in the armory of drugs
used to treat ocular fungal infections. It achieves an ex-
cellent intravitreal concentration after oral or intraven-
ous administration [36]. The usual dose of voriconazole
is 100–200 mcg in 0.1 ml sterile water. This dose
achieves a final concentration of about 25–50 mcg/ml in
the vitreous [72].
Among the azoles, the recommended dose of fluco-
nazole according to the Infectious Disease Society of
America (IDSA) guidelines for Candida endophthalmitis
is 400–800 mg daily [73]. Fluconazole is also a broad
spectrum agent with a better side effect profile than
AMB. Therefore, it has been used in place of AMB as
the first-line agent against endogenous fungal endoph-
thalmitis (EFE) as shown by Hamada et al. [74]. IDSA
recommended the use of amphotericin B along with
flucytosine for Candida endophthalmitis. Alternatively,
fluconazole can be used as well. For severe cases of
endophthalmitis or vitritis, the adjunctive use of vitrec-
tomy is recommended [73].
The duration of systemic antifungal therapy is a mini-
mum of 6 weeks but the length of therapy depends upon
the resolution of ocular lesions. With severe involvement,
usually a longer duration of therapy may be required.
Other endogenous fungal endophthalmitis
Treatment in immunocompromised patients includes
systemic antifungal therapy (e.g., amphotericin or vori-
conazole). If the patient is able to tolerate surgery, vi-
trectomy and removal of intraocular lens should be
performed followed by intravitreal antifungal therapy
using amphotericin or voriconazole. However, if the pa-
tient cannot tolerate surgery, intravitreal injection with
amphotericin or voriconazole should be administered
initially and repeated as needed. Voriconazole has been
used to treat fungal infections resistant to fluconazole
and amphotericin B [75]. In an in vitro study, voricona-
zole showed 100 % activity against Aspergillus species,
Paecilomyces species, and Fusarium species [76].
Other reports also stated successful treatment of Fu-
sarium and Aspergillus endophthalmitis using vorico-
nazole [77, 78].
IDSA guidelines for the treatment of Aspergillus
endophthalmitis recommend the use of IV amphoter-
icin B with addition of intravitreal amphotericin B
and pars plana vitrectomy for sight-threatening cases
[79]. The recommended alternate therapy is systemic
or intravitreal voriconazole. Table 3 summarizes the
role of antifungal agents along with their sensitivity
profiles.
Pars plana vitrectomy
PPV is a commonly used modality in the treatment of
EE. It is recommended for severe and sight-threatening
Candida, Aspergillus, or bacterial endophthalmitis [5,
73, 79]. It serves as a diagnostic as well as therapeutic
purpose. It may remove a large number of organisms
seeding the vitreous cavity thus lowering the disease
burden [2, 5, 80]. An intravitreal injection of drugs
may also be given while performing the surgery. The
decision regarding vitrectomy is usually based on the
clinician’s judgment. However, almost all reported
cases where a therapeutic vitrectomy was performed
are of patients presenting with either sight-threatening
disease or of those that were irresponsive to systemic ther-
apy [15, 17, 49, 52, 67, 80].
Table 3 Commonly used intravitreal antifungal drugs employed for pharmacotherapy of fungal endogenous endophthalmitis along
with their sensitivity
Drug Intravitreal dose Systemic dose Candida Aspergillus Others
A. Polyene
Amphotericin B 5 μg/0.1 ml 0.5–0.7 mg/kg (IV) ++ +
B. Imidazoles
Miconazole 25–50 μg/0.1 ml – + +
Itraconazole 5 μg/0.05 ml 200–400 mg/day (oral) + +
200 mg/day (IV)
Voriconazole 50–200 μg/0.1 ml 200 mg twice daily (oral) +++ ++ Fusarium +
3–6 mg/kg (IV) twice daily
C. Pyrimidine
5-Flucytosine 2.25 mg/0.1 ml 25–37.5 mg/kg/day − +
D. Echinocandins
Caspofungin – 50 mg/day + +
IV intravenous
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Zhang et al. has reported better visual outcomes in
cases that underwent early vitrectomy [52]. Decision of
early vitrectomy has also been associated with a decrease
in incidence of retinal detachment and evisceration or
enucleation [15, 81]. Sato et al. recommended the use of
vitrectomy for Candida EE before stage IV according to
Ishibashi’s classification [47]. In cases of bacterial EE,
vitrectomy is generally performed when there is no re-
sponse to intravitreal antibiotics within 48 h or when the
eye condition continues to decline or with a worse grade
of RAPD [26]. Yoon et al. and Ishii et al. suggested
aggressive treatment including early vitrectomy for
Klebsiella endophthalmitis might lead to better final out-
comes [82, 83]. On the other hand, Sheu et al. found no
association between the timing of vitrectomy and visual
outcome in Klebsiella endophthalmitis [25]. However,
they still suggested the use of surgical intervention, espe-
cially in patients with anterior chamber inflammation
that did not respond well to intravitreal antibiotics.
Role of corticosteroids
Currently, no clear guidelines exist regarding the use of
corticosteroids in endophthalmitis. Inflammation, al-
though essential in combating invading organisms, may
end up damaging retinal structures [84]. Steroids have
multiple anti-inflammatory effects which include but are
not limited to decrease in leucocyte recruitment, attenu-
ating production of various inflammatory cytokines and
stabilizing membrane barriers including blood-retinal
barrier [85].
Clinical studies have reported controversial results on
the use of intravitreal as well as systemic steroids for
endophthalmitis [2]. In two case series by Jackson et al.,
better visual outcomes were reported in the patients
who received additional treatment with intraocular ste-
roids [11, 13]. An interim safety analysis of a prospective
multicenter randomized placebo-controlled trial of IVT
dexamethasone as an adjuvant therapy for endophthal-
mitis did not report any safety risks associated with the
use of steroids [85]. On the other hand, Shuwan lee et
al. reported no significant association of the use of sys-
temic steroids with better visual outcomes [86]. Shah et
al. reported a significantly reduced likelihood of obtain-
ing a three-line improvement in visual outcomes follow-
ing the use of intravitreal steroids in patients with
postoperative endophthalmitis [87].
In summary, data on the use of steroids in endophthal-
mitis is limited, and the results of studies are conflicting.
Therefore, judicious use of steroids is recommended.
Prognosis
In general, EE does not have a favorable prognosis and
results in complete vision loss, especially if the diagnosis
is missed early on and therefore treatment is delayed
[21]. Zenith et al. reported that the eyes with bacterial
EE had a worse outcome with more patients requiring
enucleation or evisceration compared to patients with
fungal EE [21]. The major risk following vitreous aspir-
ate in patients with EE is high incidence of retinal de-
tachment. Surgery for retinal detachment in these cases
is difficult, and there is a need for long-term tamponade
in such patients post vitrectomy [88].
A clinician has to maintain a very high level of suspi-
cion when a patient with a possible risk factor presents
in association with decreased vision and vitreoretinal
changes on examination. Early diagnosis and treatment
has been associated with 64 % of patients having visual
acuity of counting fingers (CF) or better in one study for
bacterial EE [28]. This is well above the percentage of
patients reported with similar improvement before this
study [11]. Itoh et al. also reported that early aggres-
sive treatment can lead to good visual outcomes [89].
Early vitrectomy within 2 weeks of presentation, espe-
cially in severe cases or when suspecting a highly
virulent organism, can lead to a good overall outcome
[79, 82, 83, 86, 90].
Virulence of the organism plays an important role in
the visual outcome [15]. Aspergillus and other molds
cause more aggressive disease compared to yeasts and
therefore carries a worse prognosis [16, 18, 30, 43, 91].
Similarly MRSA endophthalmitis has been reported to
be associated with significant mortality [28]. The associ-
ation of MRSA endophthalmitis with visual outcome has
been variable, with some studies reporting no associ-
ation while others associating it with worse visual
outcome [28, 92, 93]. Connell et al. found that all the
patients in their study needing enucleation were infected
by Klebsiella [10].
In a study conducted to determine factors resulting in
poor visual outcome, worse initial visual acuity and cen-
trally located lesions were found to be associated with
poor visual outcomes [81]. The same study showed that
early vitrectomy prevented the development of retinal
detachment. The results of another study in patients
with fungal EE showed that early stages were associated
with better prognosis. This underscores the importance
of detecting and promptly treating the disease at early
stages to preserve visual acuity [80]. According to Ang
et al., the main prognostic factor in Klebsiella EE is the
presence of hypopyon [26]. Other prognostic factors
found in the same study include rapid onset of ocular
symptoms, unilateral involvement, and panophthalmitis.
Another study found no association between final visual
acuity (log MAR values) and diabetes, causative organ-
ism, source of infection, and performance of vitrectomy
[15]. However, the study did report better final visual
outcomes in patients with initial visual acuity better than
counting fingers.
Sadiq et al. Journal of Ophthalmic Inflammation and Infection  (2015) 5:32 Page 8 of 11
Conclusions
EE is an ophthalmological emergency that requires
prompt diagnosis and management. Figure 4 depicts a
simplified flow chart for the diagnosis and management
of EE. The main challenges in the management of EE
are early identification and delivering an adequate con-
centration of the drug in the vitreous cavity. It may be
possible to overcome this challenge with direct intravit-
real administration of the antibiotic.
Systemic therapy is used to treat the focus of infection
causing the metastatic spread of the organism to the
ocular cavity. In mild cases of EE, systemic therapy is
the mainstay of treatment. However, in severe cases, sys-
temic therapy is adjuvant to the more aggressive intravit-
real administration of drugs.
PPV has a diagnostic as well as therapeutic role in the
management of EE. Vitrectomy may be strongly consid-
ered as a treatment option if there is no response to sys-
temic or local therapy within 24–48 h of presentation or
if the patient has possible worsening. Visual acuity, sys-
temic debility, etiology of infection, and ocular examin-
ation must guide the decision to intervene in such cases.
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